'The Clatterbridge Cancer Centre

About us

Bringing together our excellent multidisciplinary research community, we aim to transform collaborative cancer research to benefit patients.

With one in two people predicted to get cancer in their lifetime, cancer is internationally agreed as one of the challenges of our time. Within the UK, cancer incidence in Liverpool is higher than in most comparable cities.

The Liverpool Cancer Research Institute (LCRI), builds on the success of previous strategic cancer research initiatives in the region, and aims to further consolidate the existing strengths in biomedical and translational cancer research in Liverpool, grow its capability and accelerate the translation of research into improved patient outcomes.

Key aims:

  • Create the optimal environment for a thriving integrated academic/clinical cancer research community, collaborating across all faculties of the University covering the spectrum of biomedical and translational research 
  • Support the development of research leaders and teams from all relevant disciplines to take forward strategic cancer research programmes in the region 
  • Ensure research and innovation programmes remain relevant through the development of strong patient and public involvement by adopting a patient centred approach and proactive stakeholder engagement.

At the heart of the endeavour is a three-way partnership between the region’s three biggest stakeholders in cancer research, namely the University of Liverpool (UoL), The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) and North West Cancer Research (NWCR), working alongside Liverpool Health Partners.

An inclusive research framework

The ultimate goal of our research is to generate the knowledge that will translate to patient benefit and improve clinical practice.

LCRI functions as a translational research engine in which clinical themes provide a bi-directional conduit linking fundamental science, experimental medicine and clinical research. In this way, the LCRI drives and facilitates the translation of scientific discoveries into new tests and treatments (forward translation), whilst at the same time generating clinical questions and patient samples to steer and facilitate fundamental research (reverse translation).

Liverpool Cancer Research Institute Research Diagram

The LCRI encompasses all cancer research activity with UoL and all translational research in CCC. Within this inclusive framework, several translational research epicentres have been identified by virtue of their established critical mass and/or strategic importance to the partner organisations. These include the CRUK/NIHR Liverpool Experimental Cancer Medicine Centre, the Liverpool Head and Neck Centre, hepato-pancreato-biliary cancer, haemato-oncologylung cancer and ocular oncology.

Other tumour sites such as breast, colorectal and brain provide additional translational research activity and capability with potential for further development. Areas of strength in cross-cutting science include early cancer detection / diagnosis, molecular mechanisms of cancer progression, tumour microenvironment / immuno-oncology, and cancer pharmacology / therapy failure.

LCRI - a partnership within the Liverpool Academic Health Science System

Liverpool Cancer Research Institute Diagram

Strategic alignment between the UoL, CCC and NWCR ensures that available resources and expertise are optimally harnessed to support LCRI objectives, while connectivity with the wider local and regional health and biomedical research ecosystem is provided by:  

  • The involvement of LHP – a local partnership of 8 NHS Trusts and 4 Higher Education Institutions 
  • The footprint of CCC – provides regional cancer services to the whole of Cheshire and Merseyside 
  • The footprint of NWCR –funds research across the north west of England and North Wales 
  • Close links with the Cheshire and Merseyside Cancer Alliance and NIHR Clinical Research Network North West Coast

The LCRI Leadership Team 

The LCRI Leadership Team has been established as a permanent and formal management team specifically to oversee the development and implementation of the cancer research and innovation strategy for LCRI. 

LCRI Director 

Prof Andrew Pettitt

LCRI Head of Strategic Planning and Engagement 

Dr Matina Tsalavouta

Clinical Director of Research and Innovation, CCC 

Prof Nagesh Kalakonda

Director of Operations Research and Innovation, CCC 

Dr Gillian Heap

CEO, North West Cancer Research

Mr Alastair Richards 

Head of Department of Pharmacology and Therapeutics

Prof Ana Alfirevic

Early Detection theme lead

Prof Eithne Costello

LCTC Director 

Prof Carrol Gamble

Pancreas and HPB Clinical Research Theme Lead 

Prof Paula Ghaneh

Chair of ISMIB Research and Impact Committee 

Prof Roy Goodacre

Chair of ISMIB Clinical Committee

Prof Chris Halloran

Associate Pro-Vice Chancellor - Research and Impact, Faculty of Science and Engineering

Prof Laura Harkness-Brennan

Head and Neck Centre Director  

Prof Terry Jones

Immuno-oncology Research Theme Lead 

Prof Christian Ottensmeier

ECMC Director 

Prof Dan Palmer

Director of Liverpool Shared Research Facilities 

Prof Ian Prior 

Executive Dean of ISMIB, UoL 

Prof Sonia Rocha

Head of Department Molecular and Clinical Cancer Medicine, UoL 

Prof Michael Schmid

Secretary to the team 

Ms Jackie Henderson


Back to: Liverpool Cancer Research Institute